Practical Guidelines for Ethical and Policy Issues that Arise from the Clinical Application of Whole Genome Sequencing in Cancer Patients

Lim, Howard John; Virani, Alice; Fok, Alexandra; Karsan, Aly; Renouf, Daniel J.; Gelmon, Karen A.; Yip, Stephen; Chia, Stephen; Sun, Sophie; Tinker, Anna V.; Lee, S.J.; Rassekh, R.; Deyell, Rebecca J.; Roscoe, Robyn; Jones, Steven J.M.; Pleasance, Erin; Marra, Marco A.; Laskin, Janessa

doi:10.1093/annonc/mdu358.46

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To establish and evolve processes and guidelines for the management and discussion of incidental germline findings and variants of uncertain significance ( Lim et al 2014 ), we established a POG Ethics and Policy subcommittee. This subcommitte included an ethicist, genetic counselors, medical geneticists, pathologists, bioinformaticians, and medical oncologists.…”

Section: Introductionmentioning

confidence: 99%

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers

Laskin

Jones

Aparicio

et al. 2015

Cold Spring Harb Mol Case Stud

104

122

View full text Add to dashboard Cite

Given the success of targeted agents in specific populations it is expected that some degree of molecular biomarker testing will become standard of care for many, if not all, cancers. To facilitate this, cancer centers worldwide are experimenting with targeted "panel" sequencing of selected mutations. Recent advances in genomic technology enable the generation of genome-scale data sets for individual patients. Recognizing the risk, inherent in panel sequencing, of failing to detect meaningful somatic alterations, we sought to establish processes to integrate data from wholegenome analysis (WGA) into routine cancer care. Between June 2012 and August 2014, 100 adult patients with incurable cancers consented to participate in the Personalized OncoGenomics (POG) study. Fresh tumor and blood samples were obtained and used for whole-genome and RNA sequencing. Computational approaches were used to identify candidate driver mutations, genes, and pathways. Diagnostic and drug information were then sought based on these candidate "drivers." Reports were generated and discussed weekly in a multidisciplinary team setting. Other multidisciplinary working groups were assembled to establish guidelines on the interpretation, communication, and integration of individual genomic findings into patient care. Of 78 patients for whom WGA was possible, results were considered actionable in 55 cases. In 23 of these 55 cases, the patients received treatments motivated by WGA. Our experience indicates that a multidisciplinary team of clinicians and scientists can implement a paradigm in which WGA is integrated into the care of late stage cancer patients to inform systemic therapy decisions.

show abstract

Section: Introductionmentioning

confidence: 99%